Damora Therapeutics, Inc.
Damora Therapeutics, Inc. is a clinical-stage biotechnology company developing novel small-molecule therapeutics for cancer and liver diseases. The company is focused on product candidates GB1211 and GB3226, targeting areas with high unmet medical need and no disease-modifying treatment options.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenuePreclinical small-molecule program being advanced toward IND submission and later clinical development.
Clinical-stage product candidate in the company's oncology and liver disease pipeline.
Research, in-licensing and development of additional product candidates and technologies.
Potential sales, marketing, medical affairs and distribution activities if candidates are approved.
Customers
Damora does not currently sell approved products; its near-term 'customers' are regulators, clinical trial participants, and contract research/manufacturing partners that enable development. If its programs succeed, the end-market customers would be patients with cancer or liver disease, along with physicians, hospitals and third-party payors that influence adoption and reimbursement.
FDA, EMA and other agencies review preclinical and clinical data and determine whether programs can advance.
Contract research and manufacturing organizations provide trial execution, testing and drug supply.
Future end users of approved therapies if GB1211, GB3226 or other candidates reach market.
Clinical decision-makers who would adopt the therapies based on efficacy, safety and convenience.
Commercial and government payors that would determine access through coverage and reimbursement.
Strategy
The company is prioritizing GB3226 and GB1211, with GB3226 expected to advance through preclinical work and toward an IND filing. It is also seeking additional capital and potential collaborations to fund clinical development, while building the operational, regulatory and manufacturing capabilities needed for eventual commercialization.
This is the clearest near-term value-creation milestone and supports progression into clinical development.
The company expects substantial additional funding needs and has going-concern risk without financing.
Clinical-stage biotech requires regulatory, manufacturing and commercial capabilities before launch.
Pipeline value depends on patent protection, exclusivity and access to external expertise and capital.
Geography
Damora is headquartered in the United States and its development work is centered on U.S. regulatory pathways, especially FDA interactions for GB3226. The company also references EMA and other foreign regulators, and it relies on international supply chains and third-party manufacturers, which creates exposure to trade policy and cross-border operating risk.
Risks
Damora is a pre-revenue biotech with substantial going-concern and financing risk because it must fund long development cycles before any product revenue can emerge. Its business also depends on clinical success, regulatory approvals, IP protection and outsourced manufacturing, while trade restrictions and supply-chain disruptions can increase costs and delay programs.
- Insufficient financing and going-concern riskImpact: CriticalLikelihood: Medium
The company states it will require substantial additional capital and may need to cut or stop programs if funding is unavailable.
Exposure: All development programs and corporate continuity
- Clinical development and regulatory failureImpact: HighLikelihood: Medium
Product candidates must succeed in preclinical and clinical studies and obtain FDA/other approvals before commercialization.
Exposure - Outsourced manufacturing and supply-chain disruptionImpact: HighLikelihood: Medium
The company relies on third-party manufacturers and international inputs for preclinical and clinical supply.
Exposure - Intellectual property and competition riskImpact: HighLikelihood: Medium
Value depends on maintaining patents, exclusivity and freedom to operate against competing therapies and third-party IP claims.
Exposure: Pipeline protection and future commercialization
- Trade policy and geopolitical riskImpact: MediumLikelihood: Medium
Tariffs, import restrictions and geopolitical instability can raise costs and delay research or manufacturing activities.
Exposure
Accounting
Judgemental itemsManagement estimates costs for CROs, CMOs and other vendors before invoices arrive, affecting R&D expense and accrued liabilities.
Impact: Can materially shift quarterly operating loss and working capital
The company disclosed substantial doubt about its ability to continue as a going concern without additional financing.
Impact: Important for liquidity analysis and capital structure risk
Loss carryforwards and temporary differences may not be realizable without future taxable income.
Impact: Can affect tax benefit recognition and equity
Study start-up, treatment and wrap-up periods create uneven expense recognition across quarters.
Impact: Reduces comparability of period-to-period R&D spend
Similar listed companies
Publicly listed companies with a comparable business focus.
Tyra Biosciences, Inc.
TYRA · Pharmaceutical Preparations
Kymera Therapeutics, Inc.
KYMR · Biological Products, (No Diagnostic Substances)
Relay Therapeutics, Inc.
RLAY · Biological Products, (No Diagnostic Substances)
Bicara Therapeutics Inc.
BCAX · Pharmaceutical Preparations
Larimar Therapeutics, Inc.
LRMR · Pharmaceutical Preparations
Marker Therapeutics, Inc.
MRKR · Pharmaceutical Preparations
Last updated: 24/09/2026